This is a prospective randomised controlled clinical trial in patients with a fully recovered Atrial Fibrillation (AF)-mediated cardiomyopathy receiving ongoing heart failure therapy.
The study will assess whether those with AF and recovered heart function can maintain stable heart function when the heart medications are gradually reduced and discontinued. Although these heart medications are useful when the heart is weakened, it is unclear whether they are needed in the long term when the heart function has returned to normal. Patients will be randomised to either staged withdrawal of neuro-hormonal therapies or their continuation and each group will crossover at 6 months for a total study duration of 12 months. Serial assessments will include cardiac imaging, exercise testing and symptom assessments throughout the study period.